Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-[5-11C]-glutamine is a radiolabeled amino acid positron emission tomography (PET) tracer designed to study glutamine uptake and metabolism in vivo. It is used primarily for imaging tumors that exhibit increased glutaminolysis—a metabolic hallmark of many cancers, including colorectal cancer and gliomas. The tracer enables noninvasive visualization of tumor lesions by exploiting the elevated demand for glutamine in rapidly proliferating cancer cells. Mechanistically, it acts as a substrate analog for cellular glutamine transporters and metabolic pathways involved in protein synthesis and energy production via the tricarboxylic acid (TCA) cycle. In clinical studies, L-[5-11C]-glutamine PET has demonstrated safety and utility for detecting metastatic lesions in multiple organs, with potential applications in patient selection and monitoring response to therapy[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-[5-11C]-glutamine.